ClinicalTrials.gg
Not yet recruitingNCT07921550ALL-CD22-PhUpdated Nov 6, 2026

Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL

An interventional study of Inotuzumab ozogamicin (INO) and Venetoclax (VEN) in ALL, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
14 Years to 60 Years
Sex
All
01

Study summary

This prospective, open-label, single-arm study evaluates whether reduced-intensity induction with venetoclax plus inotuzumab ozogamicin (2VIP) followed by one cycle of blinatumomab improves the 8-week NGS-MRD-negative complete remission rate in adolescents and adults (age 14-60 years) with newly diagnosed, untreated, CD22-positive, Philadelphia chromosome-negative B-cell ALL. A Simon two-stage design will enroll up to 43 evaluable patients.

02

Conditions studied

  • ALL

Keywords

  • B-ALL
  • CD22
  • inotuzumab ozogamicin
03

In context

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 410 studies on the registry; 291 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, untreated (except prednisone/hydroxyurea) Ph-negative ALL by morphology and immunophenotype.
  • CD22-positive (≥20% blasts).
  • Age ≥14 and ≤60 years.
  • ≤2.
  • Effective if of .
  • Organ function: \<1.5×; /ALT ≤2.5×ULN; creatinine \<2×ULN; myocardial enzymes \<2×ULN; amylase ≤1.5×ULN; >45%.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Burkitt lymphoma/leukemia.
  • Acute leukemia of ambiguous lineage.
  • Pregnancy.
  • Uncontrolled active infection.
  • History of pancreatitis.
  • Uncontrolled diabetes ( >7.5%).
  • Active GI bleeding within 6 months. -
  • Arterial/venous thrombosis within 6 months.
  • Known .
  • Psychiatric disease precluding compliance.
  • Other conditions judged unsuitable by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    2VIP induction followed by blinatumomab, then pediatric-inspired chemo

    Induction 2VIP: Inotuzumab 1 mg d4 and d11; Vincristine 1.4 mg/m² (max 2 mg) d1,8; Venetoclax ramp 100/200/400 mg d6-14; Prednisone 1 mg/kg/d d1-14. Immunologic consolidation: Blinatumomab 8.75 μg d1-8 then 28 μg d9-28. Subsequent CAMVL / HD-MTX-based early intensification / VDLD delayed intensification / maintenance (female 2.5 y, male 3 y). Optional additional 2VIP or Blinatumomab per protocol

    Drug: Inotuzumab ozogamicin (INO) · Drug: Venetoclax (VEN) · Drug: Vincristine · Drug: Prednisone · Biological: Blinatumomab

Interventions

06

What researchers measure

Primary outcomes

  1. 8-week NGS-MRD-negative complete remission (CR_MRD-) rate

    Proportion of evaluable patients achieving CR (or CRi/CRp counted as CR per protocol) with NGS (IG/TR clonotype) MRD negativity at week 8. Time frame: 8 weeks from start of protocol therapy.

    Time frame: up to 8 weeks

Secondary outcomes

  1. 2-week NGS-MRD-negative CR rate

    Time frame: up to 2 weeks

  2. 12-week flow-cytometry MRD-negative CR rate

    Time frame: up to 12 weeks

  3. Event-free survival (EFS)

    Time frame: Up to 5 years

  4. Overall survival (OS)

    Time frame: Up to 5 years

  5. Disease-free survival (DFS)

    Time frame: Up to 5 years

  6. Relapse-free survival (RFS)

    Time frame: Up to 5 years

  7. Cumulative incidence of relapse

    Time frame: Up to 5 years

  8. Early mortality at 4 weeks and 8 weeks

    Time frame: Up to 4 weeks and 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Pending PI confirmation

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07921550
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Nov 30, 2035 (estimated)
Last update
Nov 6, 2026

Study contacts

Hui Wei, Professor
Contact
weihui@ihcams.ac.cn
13132507161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inotuzumab Ozogamicin · Venetoclax · Blinatumomab

Start the discussion